Synterex
LightNews LightNews
banner
synterex.bsky.social
Synterex
@synterex.bsky.social
11 followers 26 following 22 posts
Synterex is a woman- and disability-owned business that provides solutions for clinical research including medical writing ✍️, project management 📋, and IT support 💻. #SynterexSolutions
Posts Replies Media Videos
synterex.bsky.social
#ThrowbackThursday to the time we partnered with a growing #Biotech to provide comprehensive regulatory document and health authority response support across multiple study phases.

Here’s to continuing the work that helps innovative therapies move closer to patients who need them!
February 6, 2026 at 2:15 AM
synterex.bsky.social
Here are 5 tips for managing quality references with @clarivate.com's #EndNote:
1️⃣ Search & import references directly
2️⃣ Master Cite While You Write (CWYW)
3️⃣ Maintain your library
4️⃣ Customize output styles
5️⃣ Press Shift + F3 for capitalization options

Let's write: www.synterex.com/services/med...
December 22, 2025 at 2:16 PM
synterex.bsky.social
Every dollar saved by automating your operations and documentation translates into additional months of clinical runway. Learn more about our AI-enabled document authoring and management software AgileWriter.ai® today:www.synterex.com/contact
#ClinicalTrialss#ClinicalRunwayy#AIinHealthcaree
November 30, 2025 at 5:19 PM
synterex.bsky.social
When it comes to writing clinical documents for #Regulatory submissions, maintaining consistency and compliance is critical.

Quillyx templates ensure documents meet the technical requirements for successful health authority submissions. Learn how: www.synterex.com/software-sol...
November 22, 2025 at 9:07 PM
synterex.bsky.social
By automating the rote parts of your #ClinicalDocumentation operations, you can stretch both your budget and your #ClinicalRunway.

Chat with one of our #MedicalWriters or IT team members about what AgileSuite can do for your organization: www.synterex.com/contact
November 22, 2025 at 2:15 AM
synterex.bsky.social
We're honored to be selected as a 2025 #ComcastRISE recipient! In addition to a $5,000 monetary grant, we also receive #SmallBusiness consultation, access to educational tools, technology and equipment services, and media support, including a 180-day TV commercial campaign.

#TechnologyMakeover
October 28, 2025 at 8:11 PM
synterex.bsky.social
In a landscape where every day counts, the ROI on high-quality #MedicalWriting is real and measurable. Read our LinkedIn post for info about building trust with regulators, stakeholders, and patients: www.linkedin.com/company/synt...

#RegulatoryAffairs #DrugDevelopment #ClinicalDevelopment
October 24, 2025 at 4:32 PM
synterex.bsky.social
Compliance is non-negotiable in this industry. But with the right integration strategy and the right partners, AI becomes a force multiplier. Read our post on LinkedIn for more insights: www.linkedin.com/company/synt...

#RegulatoryWriting #Compliance #ClinicalDevelopment #QualityAssurance
October 17, 2025 at 2:15 PM
synterex.bsky.social
In rare diseases, the “n of 1” matters, and efficacy narratives help tell that story with clarity and impact. For more on #EfficacyNarratives in #RareDiseases, read our latest LinkedIn post: www.linkedin.com/feed/update/...

#ClinicalDevelopment #RegulatoryStrategy #OrphanDrugs
Services | Synterex | Synterex
In rare disease development, regulatory decision-making often hinges on limited, non-traditional data. Common challenges that arise in the rare disease space include small sample sizes, single-arm or ...
www.linkedin.com
October 9, 2025 at 5:15 PM
synterex.bsky.social
When people think about #RegulatoryWriting, they often focus on the what: protocols, CSRs, CTD modules. But the real value comes from the how and the outcomes it enables.

Whatever obstacles your team is facing, we are here to help: www.synterex.com/services/pro...

#MedicalWriting #LifeSciences
September 29, 2025 at 6:30 PM
synterex.bsky.social
AI tools are evolving at breakneck speed, but how far can they take us in crafting better, faster manuscripts?

Here's a look at where we're headed: www.synterex.com/post/dear-ai...

#AIinHealthcare #GenAI #EthicalAI #ClinicalResearch
Dear AI, Draft This Manuscript: The (Very Near) Future of Scientific Writing
In academic and clinical research, time is a precious commodity—and so is clarity. With artificial intelligence (AI) writing tools evolving at breakneck speed, researchers and…
www.synterex.com
September 22, 2025 at 12:15 PM
synterex.bsky.social
In regulatory affairs, compliance is only as strong as your integration across teams and systems.

For more effective focus on your people and processes, collaborate with our experts at Synterex. Learn more: www.synterex.com/services/reg...

#RegulatoryAffairs SynterexSolutions
September 18, 2025 at 11:15 AM
synterex.bsky.social
At Synterex, we work with teams to preempt common challenges in #ClinicalDocumentation projects by:

🟢 Establishing structured, realistic review schedules
🟢 Aligning data availability with document timelines
🟢 Building in flexibility without compromising quality

#MedicalWriting #LifeSciences
September 11, 2025 at 2:45 PM
synterex.bsky.social
Unsure how to navigate GDPR or the EU AI Act in your clinical trials? There's a webinar for that! Join us and AVS Life Sciences in two weeks for "Smarter Tools, Stricter Rules." Register now: us02web.zoom.us/meeting/regi...

#GDPR #EUAIAct #ClinicalTrials
September 10, 2025 at 5:06 PM
synterex.bsky.social
Bringing new #VeterinaryProducts to the market is just as complex as with a human medicine, sometimes even more so. At Synterex, our #RegulatoryAffairs consulting team has the experience and expertise to get you there.

Learn more: www.synterex.com/services/vet....
August 22, 2025 at 4:23 PM
synterex.bsky.social
Pharma analyst George El-Helou recently told Clinical Trials Arena that, despite industry innovation, #Regulatory guidelines "still tend to be reactive rather than proactive."

Get ahead of the regulatory curve with #AgileWriter now: www.synterex.com/software-sol....
August 18, 2025 at 6:04 PM
synterex.bsky.social
Regulatory submissions and health authority interactions seem to only get more and more complex.

Read our new blog post to learn about #AgileWriter and AI in #StructuredContent management: www.synterex.com/post/structu....
August 6, 2025 at 4:45 PM
synterex.bsky.social
Psychological priming is a phenomenon where exposure to one stimulus influences the response to another.

How does it apply to #ClinicalDocumentation? Learn more: www.synterex.com/post/psychol...
August 1, 2025 at 9:03 PM
synterex.bsky.social
If you've visited our website in the last few weeks, then you were one of the first to see our new look. Our new website improves user experience, increases accessibility, and shares more about us in order to better serve our clients.

Head to www.synterex.com to let us know what you think!
July 14, 2025 at 12:35 PM
synterex.bsky.social
We've been selected as a 2025 Fierce DEI Awards winner for Leadership in Health Equity by #FierceHealthcare! Thanks to all the team members, partners, and clients who helped get us here.

Learn more: www.fiercehealthcare.com/book/fierce-...

#FierceHealthcare #FierceDEIAwards #HealthEquity #DEI
2025 Fierce DEI Awards
The healthcare and life sciences industries’ collective push toward diversity, equity and inclusion continues as organizations recognize the business advantages and the ethical imperative. Multiple st...
www.fiercehealthcare.com
June 18, 2025 at 10:22 PM
synterex.bsky.social
To move AI from novelty to a strategic asset in #MedicalWriting, the industry needs to not only adopt the tools but rethink its processes, responsibilities, and value.

Our President, Jeanette Towles, contributed to an #AMWA paper on this topic: amwajournal.org/index.php/am....
June 15, 2025 at 4:35 PM
synterex.bsky.social
The FD&C Act requires all new drugs to undergo an intensive review process by the FDA. However, there are gaps in the guidance/regulations for drug investigations involving children of varying ages.

Download our #whitepaper on DIA marketplace for more info: marketplace.diaglobal.org/listing/synt...
(White Paper) This One’s for the Children: Progress in Pediatric Drug Development in the United States
Prior to the FD&C Act, pharmaceutical companies were not required to provide proof of drug safety or a disclosure of all active ingredients. Since then, all new drugs undergo an intensive review p...
marketplace.diaglobal.org
May 15, 2025 at 4:18 PM